What is Interpace Biosciences Inc's earnings per share (EPS)?

Interpace Biosciences Inc (IDXG) reported diluted earnings per share of $0.89 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Interpace Biosciences Inc Financials

IDXG

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Interpace Biosciences Inc (IDXG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 56/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Interpace Biosciences Inc has an operating margin of 10.5%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 46/100, indicating healthy but not exceptional operating efficiency. This is down from 17.3% the prior year.

Growth

Interpace Biosciences Inc's revenue declined 17.5% year-over-year, from $46.9M to $38.7M. This contraction results in a growth score of 4/100.

Leverage

Interpace Biosciences Inc carries a low D/E ratio of 0.51, meaning only $0.51 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Interpace Biosciences Inc's current ratio of 1.94 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Interpace Biosciences Inc has a free cash flow margin of 14.1%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

100

Interpace Biosciences Inc earns a strong 109.9% return on equity (ROE), meaning it generates $110 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Altman Z-Score Distress

-4.17

Interpace Biosciences Inc scores -4.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($54.2M) relative to total liabilities ($11.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

4/9

Interpace Biosciences Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.24x

For every $1 of reported earnings, Interpace Biosciences Inc generates $0.24 in operating cash flow ($5.8M OCF vs $24.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

24.3x

Interpace Biosciences Inc earns $24.3 in operating income for every $1 of interest expense ($4.1M vs $168K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$38.7M

YoY-17.5%

5Y CAGR+3.6%

10Y CAGR+15.2%

Interpace Biosciences Inc generated $38.7M in revenue in fiscal year 2025. This represents a decrease of 17.5% from the prior year.

EBITDA

$4.5M

YoY-46.4%

Interpace Biosciences Inc's EBITDA was $4.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.4% from the prior year.

Net Income

$24.6M

YoY+266.7%

Interpace Biosciences Inc reported $24.6M in net income in fiscal year 2025. This represents an increase of 266.7% from the prior year.

EPS (Diluted)

$0.89

Interpace Biosciences Inc earned $0.89 per diluted share (EPS) in fiscal year 2025. This represents an increase of 122.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$5.5M

YoY+45.2%

Interpace Biosciences Inc generated $5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.2% from the prior year.

Cash & Debt

$2.5M

YoY+71.5%

5Y CAGR-2.0%

10Y CAGR-11.3%

Interpace Biosciences Inc held $2.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

28M

Interpace Biosciences Inc had 28M shares outstanding in fiscal year 2025. This represents an increase of 528.2% from the prior year.

Margins & Returns

Gross Margin

62.3%

YoY-1.5pp

5Y CAGR+29.2pp

10Y CAGR+35.6pp

Interpace Biosciences Inc's gross margin was 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.

Operating Margin

10.5%

YoY-6.7pp

5Y CAGR+91.0pp

10Y CAGR+439.0pp

Interpace Biosciences Inc's operating margin was 10.5% in fiscal year 2025, reflecting core business profitability. This is down 6.7 percentage points from the prior year.

Net Margin

63.5%

YoY+49.2pp

5Y CAGR+145.1pp

10Y CAGR+207.9pp

Interpace Biosciences Inc's net profit margin was 63.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.2 percentage points from the prior year.

Return on Equity

109.9%

10Y CAGR+245.2pp

Interpace Biosciences Inc's ROE was 109.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$642K

YoY-5.0%

5Y CAGR-25.5%

10Y CAGR-11.9%

Interpace Biosciences Inc invested $642K in research and development in fiscal year 2025. This represents a decrease of 5.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$356K

YoY-59.4%

5Y CAGR-25.7%

10Y CAGR+0.1%

Interpace Biosciences Inc invested $356K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.4% from the prior year.

IDXG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$38.7M-17.5%	$46.9M+17.2%	$40.0M+25.7%	$31.8M-3.9%	$33.1M+2.2%	$32.4M
Cost of Revenue	$14.6M-14.1%	$17.0M+13.5%	$15.0M+10.1%	$13.6M-4.9%	$14.3M-34.0%	$21.7M
Gross Profit	$24.1M-19.4%	$29.9M+19.4%	$25.1M+37.4%	$18.2M-3.0%	$18.8M+75.3%	$10.7M
R&D Expenses	$642K-5.0%	$676K+6.3%	$636K-9.5%	$703K-52.9%	$1.5M-46.6%	$2.8M
SG&A Expenses	$9.5M-0.1%	$9.5M+1.3%	$9.4M-14.7%	$11.0M+2.5%	$10.7M-41.2%	$18.2M
Operating Income	$4.1M-49.6%	$8.1M+105.0%	$4.0M+209.4%	-$3.6M+42.9%	-$6.3M+75.7%	-$26.1M
Interest Expense	$168K	N/A	-$112K+29.1%	-$158K+68.1%	-$496K-190.3%	$549K
Income Tax	-$21.2M-530350.0%	$4K-76.5%	$17K-41.4%	$29K+104.1%	-$705K-1430.2%	$53K
Net Income	$24.6M+266.7%	$6.7M+243.0%	$2.0M+108.9%	-$22.0M-46.9%	-$14.9M+43.5%	-$26.5M
EPS (Diluted)	$0.89	$0.40-11.1%	$0.45+108.7%	$-5.18	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$8.8M-5.2%	$9.2M-19.8%	$11.5M-7.2%	$12.4M+0.9%	$12.3M+2.1%	$12.0M+18.3%	$10.2M+0.4%	$10.1M
Cost of Revenue	$3.3M-16.2%	$4.0M-4.6%	$4.1M-8.0%	$4.5M+2.5%	$4.4M+3.7%	$4.2M+9.5%	$3.9M+1.3%	$3.8M
Gross Profit	$5.4M+3.1%	$5.3M-28.4%	$7.4M-6.8%	$7.9M+0.1%	$7.9M+1.2%	$7.8M+23.7%	$6.3M0.0%	$6.3M
R&D Expenses	$150K-13.3%	$173K-2.3%	$177K-8.8%	$194K-2.5%	$199K+36.3%	$146K+6.6%	$137K-9.9%	$152K
SG&A Expenses	$2.1M-22.7%	$2.7M+4.4%	$2.5M-0.7%	$2.6M+1.2%	$2.5M+18.5%	$2.1M-4.4%	$2.2M+21.0%	$1.9M
Operating Income	$1.1M+344.7%	-$468K-125.6%	$1.8M-11.3%	$2.1M-10.4%	$2.3M-12.6%	$2.6M+136.3%	$1.1M-25.2%	$1.5M
Interest Expense	$30K-38.8%	$49K-37.2%	$78K	N/A	$141K-19.9%	$176K-10.7%	$197K+1085.0%	-$20K
Income Tax	-$11K	N/A	$18K+325.0%	-$8K-300.0%	$4K0.0%	$4K0.0%	$4K-20.0%	$5K
Net Income	$911K+242.3%	-$640K-138.9%	$1.6M-12.4%	$1.9M+12.2%	$1.7M-31.2%	$2.4M+244.2%	$708K-33.6%	$1.1M
EPS (Diluted)	$0.03+121.4%	$-0.14-333.3%	$0.06	N/A	$0.38-30.9%	$0.55+243.8%	$0.16	N/A

IDXG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$33.8M+128.8%	$14.8M+12.8%	$13.1M-17.9%	$16.0M-58.4%	$38.4M-15.9%	$45.7M
Current Assets	$9.9M-15.9%	$11.8M+13.0%	$10.4M-14.3%	$12.2M-0.1%	$12.2M-13.9%	$14.1M
Cash & Equivalents	$2.5M+71.5%	$1.5M-58.2%	$3.5M-27.5%	$4.8M+80.7%	$2.7M-3.6%	$2.8M
Inventory	$1.1M-8.0%	$1.2M-1.3%	$1.2M+0.2%	$1.2M+48.4%	$825K-59.8%	$2.1M
Accounts Receivable	$5.6M-33.9%	$8.5M+68.3%	$5.1M+0.9%	$5.0M+7.7%	$4.7M-41.8%	$8.0M
Goodwill	N/A	N/A	N/A	N/A	$8.4M0.0%	$8.4M
Total Liabilities	$11.5M-32.5%	$17.0M-75.2%	$68.7M-7.3%	$74.1M-8.4%	$80.8M+8.1%	$74.8M
Current Liabilities	$5.1M-51.9%	$10.6M-7.2%	$11.4M-19.9%	$14.3M-8.9%	$15.7M-14.0%	$18.2M
Long-Term Debt	N/A	N/A	N/A	$1.8M+255.4%	$520K-85.9%	$3.7M
Total Equity	$22.4M+1108.7%	-$2.2M+96.0%	-$55.5M+4.4%	-$58.1M-36.9%	-$42.4M-45.9%	-$29.1M
Retained Earnings	-$210.8M+10.4%	-$235.4M+2.8%	-$242.1M+2.8%	-$249.0M-9.7%	-$227.1M-7.0%	-$212.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$12.0M-2.4%	$12.3M-14.9%	$14.5M-2.0%	$14.8M+5.4%	$14.0M+8.2%	$13.0M+6.8%	$12.1M-7.4%	$13.1M
Current Assets	$9.1M-3.9%	$9.5M-18.4%	$11.7M-1.0%	$11.8M+29.4%	$9.1M-4.2%	$9.5M+0.9%	$9.4M-9.6%	$10.4M
Cash & Equivalents	$1.4M+183.5%	$502K-58.0%	$1.2M-18.1%	$1.5M+4.4%	$1.4M+180.0%	$500K-82.2%	$2.8M-19.6%	$3.5M
Inventory	$1.1M+13.5%	$973K-19.5%	$1.2M-0.2%	$1.2M-0.7%	$1.2M-0.9%	$1.2M+6.7%	$1.2M-5.9%	$1.2M
Accounts Receivable	$6.0M-17.5%	$7.2M-17.5%	$8.8M+2.6%	$8.5M+17.2%	$7.3M+17.5%	$6.2M+24.0%	$5.0M-1.4%	$5.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.3M-9.0%	$13.5M-10.1%	$15.1M-11.4%	$17.0M-73.7%	$64.6M-1.0%	$65.3M-2.5%	$66.9M-2.5%	$68.7M
Current Liabilities	$5.9M-16.8%	$7.1M-17.6%	$8.7M-18.2%	$10.6M+79.9%	$5.9M-16.9%	$7.1M-43.7%	$12.6M+10.2%	$11.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$298K+75.4%	-$1.2M-108.4%	-$582K+73.7%	-$2.2M+95.6%	-$50.5M+3.3%	-$52.3M+4.5%	-$54.8M+1.4%	-$55.5M
Retained Earnings	-$233.5M+0.4%	-$234.4M-0.3%	-$233.7M+0.7%	-$235.4M+0.8%	-$237.3M+0.7%	-$238.9M+1.0%	-$241.4M+0.3%	-$242.1M

IDXG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$5.8M+25.5%	$4.6M+22.6%	$3.8M+149.3%	-$7.7M+11.8%	-$8.7M+37.6%	-$14.0M
Capital Expenditures	$356K-59.4%	$876K+86.4%	$470K+46.0%	$322K-9.0%	$354K-77.5%	$1.6M
Free Cash Flow	$5.5M+45.2%	$3.8M+13.6%	$3.3M+141.4%	-$8.0M+11.7%	-$9.1M+41.7%	-$15.6M
Investing Cash Flow	-$356K+59.4%	-$876K-906.9%	-$87K-101.4%	$6.2M+2070.2%	-$315K+80.0%	-$1.6M
Financing Cash Flow	-$4.4M+23.7%	-$5.8M-15.4%	-$5.0M-267.7%	$3.0M-66.6%	$9.0M-45.9%	$16.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$1.9M+272.7%	$520K-57.9%	$1.2M+4.3%	$1.2M-44.0%	$2.1M+50.7%	$1.4M+2520.7%	-$58K-105.1%	$1.1M
Capital Expenditures	$117K	N/A	N/A	$129K-75.3%	$522K+165.0%	$197K+603.6%	$28K-80.3%	$142K
Free Cash Flow	$1.8M	N/A	N/A	$1.1M-33.8%	$1.6M+32.1%	$1.2M+1503.5%	-$86K-108.6%	$998K
Investing Cash Flow	-$117K	N/A	N/A	-$129K+75.3%	-$522K-165.0%	-$197K-603.6%	-$28K+80.3%	-$142K
Financing Cash Flow	-$900K+11.2%	-$1.0M+32.5%	-$1.5M+12.1%	-$1.7M-13.8%	-$1.5M+25.0%	-$2.0M-233.3%	-$600K+76.3%	-$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IDXG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.3%-1.5pp	63.8%+1.2pp	62.6%+5.3pp	57.3%+0.5pp	56.8%+23.7pp	33.1%
Operating Margin	10.5%-6.7pp	17.3%+7.4pp	9.9%+21.2pp	-11.4%+7.8pp	-19.1%+61.3pp	-80.5%
Net Margin	63.5%+49.2pp	14.3%+9.4pp	4.9%+73.8pp	-69.0%-23.8pp	-45.1%+36.5pp	-81.6%
Return on Equity	109.9%	N/A	N/A	N/A	N/A	N/A
Return on Assets	72.6%+27.3pp	45.3%+30.4pp	14.9%+152.3pp	-137.4%-98.5pp	-38.9%+19.0pp	-57.9%
Current Ratio	1.94+0.8	1.11+0.2	0.91+0.1	0.85+0.1	0.780.0	0.77
Debt-to-Equity	0.51+8.2	-7.67-6.4	-1.24-1.2	-0.03-0.0	-0.01+0.1	-0.13
FCF Margin	14.1%+6.1pp	8.0%-0.3pp	8.3%+33.5pp	-25.2%+2.2pp	-27.4%+20.6pp	-48.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	62.1%+5.0pp	57.1%-6.9pp	64.0%+0.3pp	63.7%-0.6pp	64.3%-0.5pp	64.8%+2.8pp	62.0%-0.3pp	62.3%
Operating Margin	13.1%+18.1pp	-5.1%-20.9pp	15.9%-0.7pp	16.6%-2.1pp	18.7%-3.1pp	21.9%+10.9pp	10.9%-3.7pp	14.7%
Net Margin	10.4%+17.3pp	-6.9%-21.2pp	14.3%-0.9pp	15.2%+1.5pp	13.6%-6.6pp	20.2%+13.3pp	7.0%-3.6pp	10.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	7.6%+12.8pp	-5.2%-16.6pp	11.4%-1.4pp	12.7%+0.8pp	11.9%-6.9pp	18.8%+13.0pp	5.8%-2.3pp	8.1%
Current Ratio	1.54+0.2	1.33-0.0	1.34+0.2	1.11-0.4	1.54+0.2	1.34+0.6	0.75-0.2	0.91
Debt-to-Equity	-41.39-30.2	-11.17+14.7	-25.90-18.2	-7.67-6.4	-1.28-0.0	-1.25-0.0	-1.22+0.0	-1.24
FCF Margin	20.8%	N/A	N/A	8.5%-4.5pp	13.0%+2.9pp	10.0%+10.9pp	-0.8%-10.7pp	9.8%

Similar Companies

Stagezero Life SZLSF

$3.6M

Imd Companies ICBU

$3.8M

Leveljump Health JMPHF

$34.7M

Rennova Health RNVA

$4.3M

Hypha Labs FUNI

$3.1M

Frequently Asked Questions

What is Interpace Biosciences Inc's annual revenue?

Interpace Biosciences Inc (IDXG) reported $38.7M in total revenue for fiscal year 2025. This represents a -17.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Interpace Biosciences Inc's revenue growing?

Interpace Biosciences Inc (IDXG) revenue declined by 17.5% year-over-year, from $46.9M to $38.7M in fiscal year 2025.

Is Interpace Biosciences Inc profitable?

Yes, Interpace Biosciences Inc (IDXG) reported a net income of $24.6M in fiscal year 2025, with a net profit margin of 63.5%.

What is Interpace Biosciences Inc's EBITDA?

Interpace Biosciences Inc (IDXG) had EBITDA of $4.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Interpace Biosciences Inc's gross margin?

Interpace Biosciences Inc (IDXG) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Interpace Biosciences Inc's operating margin?

Interpace Biosciences Inc (IDXG) had an operating margin of 10.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Interpace Biosciences Inc's net profit margin?

Interpace Biosciences Inc (IDXG) had a net profit margin of 63.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Interpace Biosciences Inc's return on equity (ROE)?

Interpace Biosciences Inc (IDXG) has a return on equity of 109.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Interpace Biosciences Inc's free cash flow?

Interpace Biosciences Inc (IDXG) generated $5.5M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Interpace Biosciences Inc's operating cash flow?

Interpace Biosciences Inc (IDXG) generated $5.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Interpace Biosciences Inc's total assets?

Interpace Biosciences Inc (IDXG) had $33.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Interpace Biosciences Inc's capital expenditures?

Interpace Biosciences Inc (IDXG) invested $356K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Interpace Biosciences Inc spend on research and development?

Interpace Biosciences Inc (IDXG) invested $642K in research and development during fiscal year 2025.

How many shares does Interpace Biosciences Inc have outstanding?

Interpace Biosciences Inc (IDXG) had 28M shares outstanding as of fiscal year 2025.

What is Interpace Biosciences Inc's current ratio?

Interpace Biosciences Inc (IDXG) had a current ratio of 1.94 as of fiscal year 2025, which is generally considered healthy.

What is Interpace Biosciences Inc's debt-to-equity ratio?

Interpace Biosciences Inc (IDXG) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Interpace Biosciences Inc's return on assets (ROA)?

Interpace Biosciences Inc (IDXG) had a return on assets of 72.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Interpace Biosciences Inc's Altman Z-Score?

Interpace Biosciences Inc (IDXG) has an Altman Z-Score of -4.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Interpace Biosciences Inc's Piotroski F-Score?

Interpace Biosciences Inc (IDXG) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Interpace Biosciences Inc's earnings high quality?

Interpace Biosciences Inc (IDXG) has an earnings quality ratio of 0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Interpace Biosciences Inc cover its interest payments?

Interpace Biosciences Inc (IDXG) has an interest coverage ratio of 24.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Interpace Biosciences Inc?

Interpace Biosciences Inc (IDXG) scores 56 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.